Cerebricon Announces Updates To Product Portfolio
16 May 2006
Cerebricon Ltd. is pleased to announce the following additions to its portfolio of in vivo models:
- Endothelin-1 induced stroke model
- Stroke prone rat model (SP-SMR) for primary prevention studies in stroke and ischemia
- Trigeminal Ganglia stimulation model (TGS) for migraine
In addition to the above Cerebricon announces the deletion of the Proteosome Inhibition Model for Parkinson's disease. This model was deleted due to the inability, after repeated validation studies, to maintain quality and consistency of deficit.
Cerebricon welcomes the opportunity to present its in-house validation data on these, and any other CNS disease models, to its present and prospective clients.
